BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global drug eluting balloon catheter market size is estimated to reach US$ 1 Bn in 2021.

Algenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, and Biokit Research and Development S.L.U, part of the Werfen Group, have renewed a license agreement which provides Biokit with the non-exclusive use of Algenex’ platforms, IBES® and CrisBio® for the production of human in vitro diagnostics.

Calibre Scientific is pleased to announce the acquisition of msscientific Chromatographie, a distributor of chromatography analytical products with headquarters in Berlin, Germany.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced that CEPI will provide up to an additional US$36.9 million in funding to support continued development of SCB-2019 through licensure.

Theravance Biopharma, Inc., a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will participate in a fireside chat.

Moderna, Inc. today announced the first participant has been dosed in the Phase 2/3 study of mRNA-1345, the Company’s Respiratory Syncytial Virus (RSV) vaccine candidate.

Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators.

EQRx to leverage Evotec’s unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients.

Lassen Therapeutics today announced the appointment of Puneet S. Arora, M.D. as Chief Medical Officer.

Artizan Biosciences, Inc. and Biohaven Therapeutics Ltd. today announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD).